Dengue-Fieber

Dengue-Fieber ist die häufigste tropenspezifische Viruserkrankung, die nach Deutschland importiert wird. Klinisch handelt es sich um eine akute, hoch fieberhafte Erkrankung mit Myalgien, Kopfschmerzen und variablem Exanthem. Bei Reinfektion kann es zu hämorrhagischem Dengue-Fieber oder Dengue-Schocksyndrom kommen. Eine spezifische Therapie gibt es nicht. Seit Anfang 2023 ist in Europa eine neue Impfung gegen Dengue-Fieber verfügbar.

Schlüsselwörter

Tropenerkrankung - Dengue-Virus - Dengue-Impfung - Tigermücken - Reiseanamnese

• Literatur

• 1 World Health Organisation (WHO). Ten threats to global health in 2019. Accessed October 11, 2023 at: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
• 2 Wilder-Smith A, Gubler DJ, Weaver SC. et al. Epidemic arboviral diseases: priorities for research and public health. Lancet Infect Dis 2017; 17: e101-e106
• 3 Jelinek T. CRM Handbuch Reisemedizin 2022. 58. Auflage. Düsseldorf: CRM Centrum für Reisemedizin; 2021
• 4 World Health Organisation (WHO). Dengue and severe dengue, 2023. Accessed October 11, 2023 at: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
• 5 European Centre for Disease Prevention and Control (ECDC). Dengue worldwide overview. Situation update, 23 August 2023. Stockholm: ECDC; 2023. Accessed September 25, 2023 at: https://www.ecdc.europa.eu/en/dengue-monthly
• 6 European Centre for Disease Prevention and Control (ECDC). Autochthonous transmission of dengue virus in mainland EU/EEA, 2010–present. Stockholm: ECDC; 2023. Accessed October 11, 2023 at: https://www.ecdc.europa.eu/en/all-topics-z/dengue/surveillance-and-disease-data/autochthonous-transmission-dengue-virus-eueea
• 7 World Health Organisation (WHO), Regional Office for South-East Asia. Comprehensive guideline for prevention and control of dengue and dengue haemorrhagic fever. New Delhi: WHO, Regional Office for South-East Asia; ‎2011. Accessed October 11, 2023 at: https://iris.who.int/handle/10665/204894
• 8 Katzelnick LC, Coloma J, Harris E. Dengue: knowledge gaps, unmet needs, and research priorities. Lancet Infect Dis 2017; 17: e88-e100
• 9 Oliveira LNDS, Itria A, Lima EC. Cost of illness and program of dengue: a systematic review. PLoS One 2019; 14: e0211401
• 10 Halstead S, Wilder-Smith A. Severe dengue in travellers: pathogenesis, risk and clinical management. J Travel Med 2019; 26: taz062
• 11 Wilder-Smith A, Ooi EE, Horstick O. et al. Dengue. Lancet 2019; 393: 350-363
• 12 Wharton-Smith A, Green J, Loh EC. et al. Using clinical practice guidelines to manage dengue: a qualitative study in a Malaysian hospital. BMC Infect Dis 2019; 19: 45
• 13 Tiga DC, Undurraga EA, Ramos-Castanedan J. et al. Persistent symptoms of dengue: estimates of the incremental disease and economic burden in Mexico. Am J Trop Med Hyg 2016; 94: 1085-1089
• 14 Gossner CM, Fournat E, Frank C. et al. Dengue virus infections among European travellers, 2015 to 2019. Euro Surveill 2022; 27: 2001937
• 15 European Centre for Disease Prevention and Control (ECDC). Dengue. Annual epidemiological report for 2019. Stockholm: ECDC; 2021. Accessed October 11, 2023 at: https://www.ecdc.europa.eu/sites/default/files/documents/AER-dengue-2019.pdf
• 16 Huits R, Angelo KM, Amatya B. et al. Clinical characteristics and outcomes among travelers with severe dengue : a GeoSentinel analysis. Ann Intern Med 2023; 176: 940-948
• 17 Jelinek T, Mühlberger N, Harms G. et al. Epidemiology and clinical features of imported dengue fever in Europe: sentinel surveillance data from TropNetEurop. Clin Infect Dis 2002; 35: 1047-1052
• 18 Schwartz E, Weld LH, Wilder-Smith A. et al. Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997–2006. Emerg Infect Dis 2008; 14: 1081-1088
• 19 Wilder-Smith A, Tambyah PA. Severe dengue virus infection in travelers. J Infect Dis 2007; 195: 1081-1083
• 20 Jelinek T. Dengue-Fieber. In: Jelinek T, Hrsg. Kursbuch Reisemedizin. 1. Aufl. Stuttgart: Thieme; 2012;
• 21 Suputtamongkol Y, Avirutnan P, Mairiang D. et al. Ivermectin accelerates circulating nonstructural protein 1 (NS1) clearance in adult dengue patients: a combined phase 2/3 randomized bouble-blinded placebo controlled trial. Clin Infect Dis 2021; 72: e586-e593
• 22 Tien SM, Chang PC, Lai YC. et al. Therapeutic efficacy of humanized monoclonal antibodies targeting dengue virus nonstructural protein 1 in the mouse model. PLOS Pathogens 2022;
• 23 Flores HA, Taneja de Bruyne J, O’Donell TB. et al. Multiple Wolbachia strains provide comparative levels of protection against dengue virus infection in Aedes aegypti. PLoS Pathog 2020; 16: e1008433
• 24 Utarini A, Indriani C, Ahmad RA. et al. Efficacy of Wohlbachia-infected mosquito deployments for the control of dengue. N Eng J Med 2021; 384: 2177-2186
• 25 Paul Ehrlich Institut. Denguefieber-Impfstoffe. Dengvaxia, 2023. Accessed October 11, 2023 at: https://www.pei.de/DE/arzneimittel/impfstoffe/denguefieber/dengue-inhalt.html
• 26 Thomas ST, Yoon IK. A review of Dengvaxia: development to deployment. Hum Vaccine Immunother 2019; 15: 2295-2314
• 27 Paul Ehrlich Institut. Denguefieber-Impfstoffe. Qdenga, 2023. Accessed October 11, 2023 at: https://www.pei.de/DE/arzneimittel/impfstoffe/denguefieber/dengue-inhalt.html
• 28 Thomas SJ. Is new dengue vaccine efficacy data a relief or cause for concern?. npj Vaccines 2023; 8: 55